RegeneRx enrolls first patient in Phase 2 dry eye trial
RegeneRx claims that RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tß4. The Phase 2 trial is expected
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.
The active markets in real-time freight monitoring and tracking include high-value pharmaceuticals and life sciences, consumer electronics and computing equipment, consumer packaged goods (CPG), and general high value